Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
about
Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab.Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis.Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs
P2860
Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Retrospective study of the eff ...... c HER2-positive breast cancer.
@ast
Retrospective study of the eff ...... c HER2-positive breast cancer.
@en
type
label
Retrospective study of the eff ...... c HER2-positive breast cancer.
@ast
Retrospective study of the eff ...... c HER2-positive breast cancer.
@en
prefLabel
Retrospective study of the eff ...... c HER2-positive breast cancer.
@ast
Retrospective study of the eff ...... c HER2-positive breast cancer.
@en
P2093
P2860
P1476
Retrospective study of the eff ...... ic HER2-positive breast cancer
@en
P2093
Alberto J Montero
Alicia Fanning
G Thomas Budd
Halle Moore
Jame Abraham
Paola Raska
Prasun Mishra
Robyn Stewart
Shruti R Tiwari
Stephen R Grobmyer
P2860
P2888
P304
P356
10.1007/S10549-016-3866-0
P407
P577
2016-06-20T00:00:00Z
P6179
1010109190